Cervical cancer risk reduction in the era of human papillomavirus vaccination
Cancer · 01.12.2026 · 132 (23)
DOI: 10.1002/cncr.70679 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer, online erschienen am 19.11.2026. Verfasst von Sarah A. Phillips und 5 weiteren Autor:innen. Die Arbeit nennt 26 Literaturangaben.
Abstract (Originalsprache)
Background
Human papillomavirus (HPV) vaccination status is important to consider when evaluating the population‐level impact of cervical screening uptake on cervical cancer risk, yet screening rates are rarely presented by vaccination status, limiting assessments of population‐level protection against cervical cancer.
Methods
Using females 21–39 years old from the 2019 National Health Interview Survey ( N = 4000), the authors report the proportion up‐to‐date with cervical screening stratified by age and self‐reported HPV vaccination status. Using assumptions of 85% and 70% reduction in cervical cancer risk from HPV vaccination and up‐to‐date screening status, respectively, the authors explore the population‐level reduction in cervical cancer risk from varying screening coverage by HPV vaccination status.
Results
A total of 78.4% of females were up‐to‐date with screening, 38.0% reported ever receiving an HPV vaccine, and 15.3% were both unvaccinated and not up‐to‐date with screening. Across age groups, the proportion of females up‐to‐date with screening was 6.3%–19.1% higher for vaccinated versus unvaccinated females. The relative reduction in cervical cancer risk from vaccination and screening ranged from 62.1% for females 36–39 years old to 73.1% for females 26–30 years old, compared to the absence of vaccination and screening. Despite females 21–25 years old having the lowest screening uptake, their reduction in cervical cancer risk was not the lowest due to higher vaccination levels.
Conclusions
Cervical screening rates are higher among females who were vaccinated against HPV, resulting in a higher population‐level risk of cervical cancer than expected from considering vaccination and screening rates independently. Including vaccination status in national surveillance data sets would help identify and target interventions within communities at higher risk.
Zitieren
APA
Phillips, S. A., Bandi, P., Star, J., Temkin, S. M., Smith, R. A., & Landy, R. (2026). Cervical cancer risk reduction in the era of human papillomavirus vaccination. Cancer, 132(23). https://doi.org/10.1002/cncr.70679
Vancouver
Phillips SA, Bandi P, Star J, Temkin SM, Smith RA, Landy R. Cervical cancer risk reduction in the era of human papillomavirus vaccination. Cancer. 2026;132(23). doi:10.1002/cncr.70679
BibTeX
@article{Phillips2026,
author = {Phillips, Sarah A. and Bandi, Priti and Star, Jessica and Temkin, Sarah M. and Smith, Robert A. and Landy, Rebecca},
title = {Cervical cancer risk reduction in the era of human papillomavirus vaccination},
journal = {Cancer},
year = {2026},
volume = {132},
number = {23},
doi = {10.1002/cncr.70679}
}
EUVIMED